FDA Accepts Allergan’s NDA for Bimatoprost SR in Patients With Glaucoma

Source: Allergan

Allergan announced that the FDA has accepted the company’s new drug application (NDA) for Bimatoprost Sustained-Release (SR) biodegradable implant for the reduction of IOP in patients with primary open-angle glaucoma or ocular hypertension. The FDA is expected to take action on the NDA by the end of the first half of 2020.

“With decades of experience researching and introducing innovative eye care treatments, we understand the importance of developing new and potentially sight-saving treatments for patients with glaucoma,” David Nicholson, Chief Research and Development Officer, Allergan, said in a company news release. “The NDA is based on the positive results from the ARTEMIS phase 3 studies and demonstrates our ongoing commitment to providing new treatments for patients living with glaucoma.”

In the two phase 3 ARTEMIS studies, Bimatoprost SR reduced IOP by 30 percent over the 12-week primary efficacy period, meeting the predefined criteria for non-inferiority to the study comparator. The ARTEMIS studies evaluated 1,122 subjects on the efficacy and safety of Bimatoprost SR versus timolol, a FDA standard comparator for registrational clinical trials, in patients with open-angle glaucoma or ocular hypertension. After 3 treatments with Bimatoprost SR, greater than 80 percent of patients remained treatment free and did not need additional treatment to maintain IOP control for at least 12 months. Bimatoprost SR was well tolerated in the majority of patients.

“Millions of people are living with glaucoma, a progressive disease that requires sustained IOP control to preserve vision for patients,” Robert Weinreb, MD, Chairman & Distinguished Professor of Ophthalmology and Director of the Shiley Eye Institute, San Diego, said in the news release. “Data from the ARTEMIS trials show Bimatoprost SR lowers IOP and maintains that effect for the majority of patients for one year after three administrations of the implant. Bimatoprost SR has the potential to be the first sustained-release option that could significantly shift the paradigm for treating glaucoma, a leading cause of blindness.”


Related Content


InMed Releases CBN Preclinical Results in Glaucoma
Source: InMed Pharmaceuticals